Business
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York\n \n \nEndonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York\n \n LOS ANGELES, CA--(Marketwired - Apr 13, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City.\n About Endonovo Therapeutics\n Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.\n Safe Harbor Statement\n This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as \"anticipate,\" \"believe,\" \"plan,\" \"estimate,\" \"expect,\" \"intend,\" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange ...